The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

CJC-1295 (no-DAC)

Modified GRF 1-29 · Mod GRF 1-29 · CJC-1295 no-DAC

C
Animal replicated
Research chemicalGHRH AnalogGrowth Hormone SecretagoguePeptide
RouteInjectableGray-market only
C
Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance
What it is
Modified GRF 1-29 — GHRH Analog — Pulsatile GH Secretagogue — WADA S2 — GH Stack Core Component — GHRH Analog, Growth Hormone Secretagogue, Peptide.
Why people use it
Used primarily for muscle and performance and sleep and recovery.
If you only read one thing

CJC-1295 (no-DAC) is an excellent GHRH analog for pulsatile GH stimulation in combination with a GHRP — producing the synergistic 3-5x GH pulse that makes the GH Stack so effective. The pharmacological case for it is solid; the GHRH+GHRP synergy is one of the most reproducible findings in GH axis pharmacology. The tension is entirely in the naming confusion: the DAC and no-DAC versions are in the same product category, sold by the same vendors, sometimes listed with ambiguous names, and produce completely different pharmacological profiles. A user who orders 'CJC-1295' without specifying may receive either version depending on the vendor's default interpretation. The DAC version is not wrong — it's a different compound for a different protocol. Mixing them up by accident produces a pharmacological outcome that's incompatible with the intended pulsatile GH stack protocol.

Check interactions →
Evidence reality check
Risk posture
No major flags listed
Review route-specific cautions before use.
Categories
Muscle & PerformanceSleep & Recovery
Properties
Active malignancy: cautionWADA S2Not injectable
Half-life
These four changes extend the plasma half-life from 4-7 minutes to approximately 30 minutes without meaningfully changing GHRH receptor binding affinity
Evidence
CAnimal replicated
The Three Names
CJC-1295 (no-DAC) = Modified GRF 1-29 = Mod GRF 1-29. All three refer to the same peptide. The 'CJC-1295' name technically applies to the DAC version as well (which is a different compound), causing persistent vendor and community confusion. When a vendor sells 'CJC-1295' without specifying 'no-DAC' or 'with DAC,' verify before purchasing. The peptide in virtually every GH Stack and CIT Blend community protocol is the no-DAC pulsatile form. If DAC is present, the protocol and pharmacology are fundamentally different.
The Four Substitutions
Native GHRH(1-29) has a plasma half-life of ~4-7 minutes due to rapid DPP-IV cleavage between positions 2-3. Mod GRF 1-29 makes four substitutions: Ala⁸→Gln (DPP-IV resistance), Gly¹⁵→Ala, Arg¹⁸→Ala, Gln²⁶→Ala (further protease resistance and solubility). These four changes extend the half-life to ~30 minutes while preserving GHRH receptor binding affinity and downstream Gs-cAMP signaling. The ~30-minute window is the active pulsatile window during which CJC-1295 (no-DAC) drives a discrete GH pulse.
The DAC Version
CJC-1295 WITH DAC adds a Drug Affinity Complex (DAC) that covalently binds serum albumin, extending half-life to approximately 8 days. This creates sustained, continuous (non-pulsatile) GH elevation rather than discrete GH pulses. The pulsatile protocol (inject before bed, GH pulse during sleep, clear by morning) that makes the no-DAC version work is incompatible with DAC's 8-day continuous profile. DAC blunts natural GH pulsatility, can cause receptor desensitization over long cycles, and does not pair meaningfully with a GHRP in a pulsatile protocol. The two compounds are used differently and are not interchangeable.
The GH Stack Role
CJC-1295 (no-DAC) is the GHRH component of the GH Stack (CJC-1295 no-DAC + Ipamorelin). See pbghstack_v4. The GH Stack chapter is the primary reference for combination protocol. This chapter provides the standalone CJC-1295 (no-DAC) pharmacology, structure-activity, and evidence detail that the GH Stack chapter references but does not expand on.
Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this classCompare 4 side by side →
CIT Stack
C
Same class · GHRH Analog

GH stack plus tesamorelin: a community combination built from GH-axis peptides with different regulatory identities, not a single FDA-approved product.

CJC-1295 + Ipamorelin
C
Same class · GHRH Analog

The Most Prescribed GH Secretagogue Combination in Clinical Practice — and the One Decision That Changes Everything: DAC or No DAC.

GH Secretagogue Stack
C
Same class · GHRH Analog

The DAC distinction determines whether this is a physiologic pulse strategy or a prolonged GH-axis exposure strategy.

Check interactions